Abstract

Currently, available therapies for diabetes could not achieve normal sugar values in a high percentage of treated patients. In this research project, a series of 17 benzodioxole derivatives were evaluated as antidiabetic agents; that belong to three different groups were evaluated against lipase and alpha-amylase (α-amylase) enzymes. The results showed that 14 compounds have potent inhibitory activities against α-amylase with IC50 values below 10 µg/ml. Among these compounds, 4f was the most potent compound with an IC50 value of 1.11 µg/ml compared to the anti-glycemic agent acarbose (IC50 6.47 µg/ml). On the contrary, these compounds showed weak or negligible activities against lipase enzyme. However, compound 6a showed the best inhibitory anti-lipase activity with IC50 44.1 µg/ml. Moreover, all the synthesized compounds were undergone Molinspiration calculation, and the result showed that all compounds obeyed Lipinski’s rule of five. Molecular docking studies were performed to illustrate the binding interactions between the benzodioxole derivatives and α-amylase enzyme pocket. Related to the obtained results it was clear that the carboxylic acid, benzodioxole ring, halogen or methoxy substituted aryl are important for the anti-amylase activities. The potent inhibitory results of some of the synthesized compounds suggest that these molecules should go further in vivo evaluation. It also suggests the benzodioxole derivatives as lead compounds for developing new drug candidates.

Highlights

  • Diabetes mellitus (DM) is a chronic metabolic disorder causing hyperglycemia, with many other disturbances in metabolizing carbohydrates and proteins

  • Antidiabetic activity The in vitro antidiabetic activity of the synthesized compounds was investigated by assessing their α-amylase inhibitory effects

  • Results showed that tested compounds have better-predicted value of molecular weight (M.Wt.) (g/mol), hydrogen bond acceptor (HBA) and donor (HBD), logP, and polar surface area (PSA) ­(A2)

Read more

Summary

Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder causing hyperglycemia, with many other disturbances in metabolizing carbohydrates and proteins. The first biological target was the COX enzymes, and the compounds with aryl acetic acids and aryl acetate (Fig. 2) were showed moderate to potent activities as COX inhibitors, and their selectivities were better than ketoprofen NSAID [20], while the benzodioxole-carboxamide derivatives (Fig. 2) were synthesized with poly-methoxyphenyl moiety as anticancer agents but their cytotoxic activities were not very potent [21].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call